Pacific Biosciences Of California(NASDAQ) PACB

Pacific Biosciences of California, Inc. helps scientists read genetic code. These systems allow researchers to study complex diseases and improve agriculture. The company helps labs solve difficult medical puzzles using DNA data.

Tools for Genetic Discovery

• Revio Systems: High-throughput sequencing instruments used by researchers to read long strands of DNA for large-scale human genome studies.
• Vega Platforms: Benchtop sequencing systems designed for smaller laboratories to access advanced genetic data in a compact format.
• Consumable Products: Single molecule real-time (SMRT) cells and chemical reagent kits used to run genetic tests on company hardware.
• Service and Other: Technical support, instrument maintenance, and training programs provided to laboratories using the company's sequencing platforms.

Strategic Moves and New Leadership

• Sold short-read DNA sequencing technology to Illumina Cambridge Limited in January 2026 for $50.0 million in cash.
• Launched SPRQ-Nx chemistry in the second quarter of 2026 to reduce sequencing costs and improve laboratory efficiency.
• Appointed Mark Van Oene as chief executive officer in August 2026 to lead the company's organizational transition.
• Approved a restructuring plan in July 2026 to reduce the workforce by approximately 8% and lower annual operating expenses.
• Formed the HiFi Solves Global Consortium to aggregate large genetic data sets and improve the understanding of disease biology.

What Makes the Tech Unique?

PacBio uses single molecule real-time technology to capture complex genetic data with high accuracy for researchers. The company reaches a global customer base through a direct sales team in North America and Europe, supported by distribution partners in other regions.

A Look at the Numbers

• Revenue was $76.2 million for the six-month period ended June 30, 2026, down 1% year over year.
• Operating loss was $53.0 million for the six months ended June 30, 2026, down $420.8 million year over year.
• Consumables revenue reached $41.9 million for the six-month period ended June 30, 2026, up 7% year over year.
• Instrument revenue was $22.6 million for the six months ended June 30, 2026, down 10% year over year.
• Cash, cash equivalents, and investments totaled $236.9 million as of June 30, 2026.

Bottom Line

PacBio is transitioning to a more efficient operating model while focusing on its core long-read sequencing technology. The company has streamlined its leadership and portfolio to better address the demand for advanced genetic research tools in clinical and academic markets.